Nirsevimab Biosimilar - Research Grade

Human

RSV

>1mg/ml

IgG1 - kappa

CHO Cells

Motavizumab Biosimilar - Research Grade (ICH5169), Clesrovimab Biosimilar - Research Grade (ICH5441), Felvizumab Biosimilar - Research Grade (ICH5546), Gontivimab Biosimilar - Research Grade (ICH5580), Suptavumab Biosimilar - Research Grade (ICH5887)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of nirsevimab, supplied for research use only and not for human or veterinary use. Nirsevimab is a human IgG1-kappa monoclonal antibody directed against the respiratory syncytial virus (RSV) fusion (F) glycoprotein in its prefusion conformation; it also carries triple amino-acid substitutions in the Fc region that extend serum half-life. This research-grade analog reproduces the target-binding activity built around the RSV F protein and is intended for in-vitro and preclinical laboratory applications. Typical uses include serving as a positive control or reference antibody in binding, neutralisation, and epitope-competition assays, as a benchmark in the development and characterisation of anti-RSV F antibodies, and as a tool in studies of prefusion F antigen structure and stability. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities for assay standardisation and larger preclinical workflows. It is not the clinical drug and should not be used therapeutically. Respiratory syncytial virus (RSV) is an enveloped, negative-sense single-stranded RNA virus of the Pneumoviridae family and a leading cause of lower respiratory tract infection in infants, older adults, and immunocompromised individuals. Entry into host cells is mediated by two surface glycoproteins: the attachment glycoprotein (G) and the fusion (F) glycoprotein. The F protein drives fusion of the viral envelope with the host cell membrane and undergoes an irreversible conformational change from a metastable prefusion state to a stable postfusion state. The prefusion conformation displays highly neutralisation-sensitive epitopes, notably antigenic site O (site Ø) at the apex, which is the target of the most potent neutralising antibodies. Because prefusion F elicits far stronger neutralising responses than postfusion F, it is the focus of RSV vaccine and monoclonal antibody development, making it a central antigen in RSV countermeasure research.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Nirsevimab biosimilar available in bulk or gram quantities?

A: Yes — the Nirsevimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Nirsevimab suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nirsevimab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Nirsevimab that binds RSV; for research use only (RUO).